https://beta.crstoday.com/news/oyster-point-pharma-receives-fda-approval-of-tyrvaya-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2480356/daily0.7https://beta.crstoday.com/news/kriya-therapeutics-appoints-theresa-heah-md-as-chief-medical-officer-and-president-of-kriya-ophthalmology/2480354/daily0.7https://beta.crstoday.com/news/alcon-celebrates-world-sight-day-2021-in-communities-worldwide-with-programs-for-improved-access-to-eye-care/2480353/daily0.7https://beta.crstoday.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/daily0.7https://beta.crstoday.com/news/new-4-year-data-show-genentechs-enspryng-significantly-reduces-debilitating-relapses-in-people-with-neuromyelitis-optica-spectrum-disorder/2480350/daily0.7https://beta.crstoday.com/news/stephen-d-mcleod-md-selected-as-next-ceo-of-american-academy-of-ophthalmology/2480346/daily0.7https://beta.crstoday.com/news/tissuetech-grows-salesforce-to-support-footprint-expansion/2480345/daily0.7https://beta.crstoday.com/news/loveyoureyes-vision-campaign-launches-global-landmark-event-to-celebrate-world-sight-day/2480343/daily0.7https://beta.crstoday.com/news/aerie-pharmaceuticals-announces-positive-phase-3-topline-results-for-netarsudil-ophthalmic-solution-002-clinical-trial-in-japan/2480342/daily0.7https://beta.crstoday.com/news/zeiss-marks-milestone-with-more-than-5-million-eyes-treated-with-smile/2480341/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-nabs-new-indication-for-dextenza-to-include-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2480340/daily0.7https://beta.crstoday.com/news/study-1-in-10-americans-have-not-had-an-eye-exam-in-five-years-or-more/2480339/daily0.7https://beta.crstoday.com/news/pfizer-biontech-seek-fda-greenlight-for-comirnaty-in-young-children/2483645/daily0.7https://beta.crstoday.com/news/glaukos-featured-in-numerous-scientific-abstracts-at-2021-escrs/2480335/daily0.7https://beta.crstoday.com/news/oculis-appoints-dr-joanne-chang-as-global-chief-medical-officer-and-opens-hong-kong-office/2480332/daily0.7https://beta.crstoday.com/news/reports-nhs-patients-waiting-more-than-9-months-on-average-for-cataract-surgery-in-2021/2480329/daily0.7https://beta.crstoday.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/daily0.7https://beta.crstoday.com/news/alcon-presents-complete-scientific-program-at-escrs-2021/2480326/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-showcases-new-veritas-vision-system-and-presents-latest-clinical-data-at-escrs-2021/2480324/daily0.7https://beta.crstoday.com/news/hoya-vision-care-and-haag-streit-partner-to-combat-myopia/2480322/daily0.7https://beta.crstoday.com/news/orasis-pharmaceuticals-appoints-julie-speed-as-senior-vice-president-head-of-strategy-and-marketing-to-lead-commercial-growth-plan/2480321/daily0.7https://beta.crstoday.com/news/nicox-launches-new-corporate-investor-website/2480319/daily0.7https://beta.crstoday.com/news/oertli-instrumente-acquires-majority-interest-in-ophthalmic-instrument-maker-domedics-ag/2480317/daily0.7https://beta.crstoday.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/daily0.7https://beta.crstoday.com/news/drug-cocktail-significantly-reduced-severe-covid-death-in-outpatients/2483644/daily0.7https://beta.crstoday.com/news/bausch-lomb-announces-statistically-significant-topline-results-from-second-phase-3-trial-of-nov03-for-dry-eye-disease/2480310/daily0.7https://beta.crstoday.com/news/monica-jong-phd-appointed-global-professional-education-lead-myopia-at-johnson-johnson-vision/2480309/daily0.7https://beta.crstoday.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/daily0.7https://beta.crstoday.com/news/aao-updates-registration-and-vaccination-requirement-for-annual-meeting/2480306/daily0.7https://beta.crstoday.com/news/global-vision-campaign-aims-to-achieve-1-million-vision-screenings-and-eye-exams-for-world-sight-day/2480305/daily0.7https://beta.crstoday.com/news/survey-americans-are-frustrated-by-unexpected-blurry-near-vision-issues/2480303/daily0.7https://beta.crstoday.com/news/eyevensys-enters-collaboration-with-phillips-medisize-and-minnetronix-medical/2480302/daily0.7https://beta.crstoday.com/news/us-eye-adds-new-partnerships-in-virginia-north-carolina-south-carolina-and-florida/2480301/daily0.7https://beta.crstoday.com/news/fda-clears-pfizer-biontechs-covid-19-booster-dose-for-65-and-older-at-risk-groups/2483643/daily0.7https://beta.crstoday.com/news/nicox-does-not-meet-primary-or-secondary-endpoint-in-phase-2b-mississippi-blepharitis-trial/2480300/daily0.7https://beta.crstoday.com/news/pharos-capital-to-acquire-vantage-outsourcing-build-new-ophthalmology-services-platform/2480299/daily0.7https://beta.crstoday.com/news/rd-fund-launches-opus-genetics-with-19m-seed-funding-to-advance-gene-therapy-treatments-for-blinding-conditions/2480298/daily0.7https://beta.crstoday.com/news/digital-vision-and-neurolens-collaborate-to-increase-prism-specificity/2480297/daily0.7https://beta.crstoday.com/news/patricia-bath-md-inducted-into-national-inventors-hall-of-fame/2480295/daily0.7https://beta.crstoday.com/news/irisvision-unveils-streamlined-lightweight-new-design-for-award-winning-low-vision-headset/2480294/daily0.7https://beta.crstoday.com/news/aerie-pharmaceuticals-announces-the-appointment-of-interim-executive-chair-and-departure-of-chairman-and-ceo/2480293/daily0.7https://beta.crstoday.com/news/zeiss-introduces-a-series-of-innovations-and-software-applications-as-part-of-the-medical-ecosystem/2480290/daily0.7https://beta.crstoday.com/news/glaukos-announces-licensing-agreement-with-attillaps-holdings-inc/2480289/daily0.7https://beta.crstoday.com/news/tissuetech-hosts-inaugural-leadership-summit-to-discuss-best-practices-on-regenerative-medicine/2480288/daily0.7https://beta.crstoday.com/news/results-published-from-2-year-multicenter-study-illustrate-efficacy-and-safety-of-preserflo-microshunt/2480287/daily0.7https://beta.crstoday.com/news/voptica-introduces-inverted-meniscus-iol-to-improve-peripheral-vision-at-escrs/2480285/daily0.7https://beta.crstoday.com/news/luneau-technology-and-optovue-announce-merger/2480284/daily0.7https://beta.crstoday.com/news/sight-sciences-files-lawsuit-against-ivantis-for-patent-infringement/2480283/daily0.7https://beta.crstoday.com/news/vsy-biotechnology-introduces-golden-ratio-in-trifocal-iol-technology/2480282/daily0.7https://beta.crstoday.com/news/comorbid-ophthalmic-systemic-conditions-linked-with-higher-risk-of-dementia/2480281/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-announces-new-collaboration-aimed-at-eliminating-inequities-in-the-eye-care-industry/2480280/daily0.7https://beta.crstoday.com/news/aerie-announces-positive-phase-2b-study-results-for-dry-eye-product-candidate/2480279/daily0.7https://beta.crstoday.com/news/glaukos-announces-settlement-of-patent-litigation-with-ivantis/2480278/daily0.7https://beta.crstoday.com/news/uk-to-offer-covid-19-booster-vaccines-to-all-over-50s/2483642/daily0.7https://beta.crstoday.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/daily0.7https://beta.crstoday.com/news/aurion-biotech-announces-strategic-investments-in-manufacturing/2480275/daily0.7https://beta.crstoday.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/daily0.7https://beta.crstoday.com/news/scientists-say-widespread-covid-19-boosting-not-needed-for-now/2483641/daily0.7https://beta.crstoday.com/news/bausch-health-files-confidentially-for-ipos-of-eye-care-business-and-medical-aesthetics-business/2479576/daily0.7https://beta.crstoday.com/news/gensight-biologics-announces-publication-analyzing-nd4-lhon-before-lumevoq-treatment-in-phase-3-trials/2479578/daily0.7https://beta.crstoday.com/news/world-council-of-optometry-launches-myopia-management-online-resource/2479506/daily0.7https://beta.crstoday.com/news/nih-funded-robotic-cane-with-3d-camera-can-accurately-guide-user-to-chosen-location/2479504/daily0.7https://beta.crstoday.com/news/oertli-launches-updated-faros-surgical-platform/2479501/daily0.7https://beta.crstoday.com/news/clearside-biomedical-expands-xipere-license-agreement-with-arctic-vision/2479500/daily0.7https://beta.crstoday.com/news/proqr-announces-axiomer-rna-editing-licensing-and-research-collaboration-with-lilly/2479498/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-1-day-lenses/2479496/daily0.7https://beta.crstoday.com/news/coburn-technologies-launches-waterless-lens-deblocking-system-and-alloy-recovery-system/2479494/daily0.7https://beta.crstoday.com/news/tearclear-files-ind-application-to-begin-its-clinical-trial-for-tc-002-latanoprost-ophthalmic-solution/2479495/daily0.7https://beta.crstoday.com/news/eyegate-pharma-completes-target-enrollment-in-phase-2-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation/2479490/daily0.7https://beta.crstoday.com/news/od-os-introduces-teleguidance-software-for-navilas-577s-navigated-retina-laser/2479491/daily0.7https://beta.crstoday.com/news/horizon-therapeutics-initiates-phase-4-clinical-trial-evaluating-tepezza-for-the-treatment-of-chronic-thyroid-eye-disease/2479489/daily0.7https://beta.crstoday.com/news/azura-ophthalmics-appoints-steven-altschuler-md-as-chair-of-the-board/2479486/daily0.7https://beta.crstoday.com/news/schwind-installs-2000th-eye-laser/2479487/daily0.7https://beta.crstoday.com/news/glaukos-submits-supplemental-pre-market-approval-application-for-istent-infinite/2479482/daily0.7https://beta.crstoday.com/news/arvo-womens-leadership-development-program-welcomes-class-of-2021/2479483/daily0.7https://beta.crstoday.com/news/vision-health-alliance-launches-first-consumer-awareness-campaign/2479484/daily0.7https://beta.crstoday.com/news/fda-advisory-panel-set-to-review-covid-19-booster-doses/2479485/daily0.7https://beta.crstoday.com/news/is-undergraduate-ophthalmology-teaching-in-the-united-kingdom-still-fit-for-purpose/2479479/daily0.7https://beta.crstoday.com/news/ama-look-to-ophthalmology-for-a-glimpse-of-telemedicines-future/2479477/daily0.7https://beta.crstoday.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/daily0.7https://beta.crstoday.com/news/visus-therapeutics-to-host-its-first-capital-markets-day-tomorrow/2479476/daily0.7https://beta.crstoday.com/news/complexity-gaming-kicks-off-year-long-partnership-with-alcon/2479475/daily0.7https://beta.crstoday.com/news/eye-health-america-acquires-two-florida-eye-practices/2479473/daily0.7https://beta.crstoday.com/news/american-academy-of-optometry-foundation-announces-award-recipients/2479474/daily0.7https://beta.crstoday.com/news/texan-eye-enters-partnership-with-comprehensive-eyecare-partners/2479472/daily0.7https://beta.crstoday.com/news/cnet-mojo-vision-crams-its-contact-lens-with-ar-display-processor-and-wireless-tech/2479469/daily0.7https://beta.crstoday.com/news/visus-therapeutics-appoints-industry-leaders-tracy-valorie-and-dwight-moxie-to-board-of-directors/2479470/daily0.7https://beta.crstoday.com/news/sight-sciences-announces-publication-of-two-year-outcomes-of-standalone-use-of-the-omni-surgical-system-in-mild-to-moderate-open-angle-glaucoma/2479466/daily0.7https://beta.crstoday.com/news/pfizer-biontechs-covid-19-vaccine-bags-full-fda-approval/2479467/daily0.7https://beta.crstoday.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/daily0.7https://beta.crstoday.com/news/glaukos-announces-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies/2479463/daily0.7https://beta.crstoday.com/news/pfizer-biontechs-covid-19-vaccine-on-brink-of-full-fda-approval/2479464/daily0.7https://beta.crstoday.com/news/market-scope-phaco-and-flacs-upgrades-to-drive-expansion-in-cataract-equipment-market/2479462/daily0.7https://beta.crstoday.com/news/aao-proof-of-covid-19-vaccination-required-for-all-registrants-attending-annual-meeting-in-new-orleans/2479461/daily0.7https://beta.crstoday.com/news/glaucoma-research-foundation-receives-1-5-million-gift-for-collaborative-vision-restoration-initiative/2479460/daily0.7https://beta.crstoday.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/daily0.7https://beta.crstoday.com/news/eyeque-announces-series-c-closing-with-more-than-57-million-in-capital-raised/2479459/daily0.7https://beta.crstoday.com/news/visus-therapeutics-expands-ophthalmic-drug-portfolio-with-investigational-therapies-for-glaucoma-and-amd/2479457/daily0.7https://beta.crstoday.com/news/u-s-to-recommend-covid-19-vaccine-boosters-8-months-after-second-dose/2479456/daily0.7https://beta.crstoday.com/news/metrovision-receives-fda-clearance-for-monpackone-for-vision-electrophysiology/2479454/daily0.7https://beta.crstoday.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-2021-online-conference/2479453/daily0.7https://beta.crstoday.com/news/alcon-to-launch-total30-as-the-first-monthly-replacement-water-gradient-contact-lens/2479449/daily0.7https://beta.crstoday.com/news/eric-d-donnenfeld-md-of-ocli-vision-named-americas-best-eye-doctor-by-newsweek/2479447/daily0.7https://beta.crstoday.com/news/biden-urges-congress-to-let-medicare-negotiate-prescription-drug-prices/2479448/daily0.7https://beta.crstoday.com/news/coopervision-misight-1-day-contact-lens-approved-in-china/2479445/daily0.7https://beta.crstoday.com/news/tarsus-pharmaceuticals-inc-appoints-industry-leader-rosemary-a-crane-to-board-of-directors/2483624/daily0.7https://beta.crstoday.com/news/fda-clearance-for-the-new-oculus-myopia-master/2479444/daily0.7https://beta.crstoday.com/news/santen-and-sydnexis-execute-an-exclusive-licensing-agreement-for-syd-101-a-novel-investigational-treatment-for-progressive-childhood-myopia/2479443/daily0.7https://beta.crstoday.com/news/sydnexis-secures-45-million-series-b-financing/2479442/daily0.7https://beta.crstoday.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/daily0.7https://beta.crstoday.com/news/precisioneffect-acquires-pascale-communications/2479440/daily0.7https://beta.crstoday.com/news/oyster-point-pharma-announces-license-agreement-with-ji-xing-pharmaceuticals-in-greater-china/2479438/daily0.7https://beta.crstoday.com/news/rayner-announces-1000-iols-recorded-on-raypro-digital-platform/2479436/daily0.7https://beta.crstoday.com/news/righteye-launches-automated-sensorimotor-exam-for-binocular-vision-testing/2479433/daily0.7https://beta.crstoday.com/news/irisvision-names-naeem-kayani-president-chief-operating-officer/2479431/daily0.7https://beta.crstoday.com/news/oculus-supports-imi-in-raising-myopia-awareness/2479430/daily0.7https://beta.crstoday.com/news/oyster-point-pharma-names-donald-santel-as-chairman-of-the-board-of-directors/2479427/daily0.7https://beta.crstoday.com/news/eyepoint-pharmaceuticals-forms-executive-scientific-advisory-board/2479426/daily0.7https://beta.crstoday.com/news/nickelodeon-and-onesight-team-up-for-kids-eye-health-campaign/2479424/daily0.7https://beta.crstoday.com/news/topcon-announces-new-executive-appointments/2479425/daily0.7https://beta.crstoday.com/news/oertlis-catarhex-3-device-now-equipped-with-speep-pump-innovation/2479420/daily0.7https://beta.crstoday.com/news/cdc-calls-for-masks-in-schools-hard-hit-areas-even-if-vaccinated/2479417/daily0.7https://beta.crstoday.com/news/coopervision-report-shows-how-ecps-can-boost-contact-lens-trial/2479418/daily0.7https://beta.crstoday.com/news/harrow-health-acquires-patented-ophthalmic-surgical-drug-candidate-from-sintetica/2479416/daily0.7https://beta.crstoday.com/news/santen-and-iapb-taking-action-to-implement-the-first-ever-un-general-assembly-resolution-recognizing-the-link-between-eye-health-and-sustainable-development/2483623/daily0.7https://beta.crstoday.com/news/aurion-biotech-announces-iota-cell-therapy-trial/2479415/daily0.7https://beta.crstoday.com/news/study-shows-reduction-in-postoperative-halosin-patients-treated-with-tearscience-lipiflow-treatment-prior-to-bilaterial-cataract-surgery/2479413/daily0.7https://beta.crstoday.com/news/new-consumer-data-on-post-pandemic-attitudes-beliefs-reveals-opportunities-for-eye-care-community/2483622/daily0.7https://beta.crstoday.com/news/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia/2479409/daily0.7https://beta.crstoday.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/daily0.7https://beta.crstoday.com/news/bvi-announces-collaboration-with-beyeonics-vision/2479411/daily0.7https://beta.crstoday.com/news/glaukos-comments-on-the-cms-2022-proposed-physician-fee-schedule/2479412/daily0.7https://beta.crstoday.com/news/modernizing-medicine-showcases-single-screen-innovations-at-ascrs/2479405/daily0.7https://beta.crstoday.com/news/united-nations-resolution-designed-to-tackle-preventable-sight-loss/2479406/daily0.7https://beta.crstoday.com/news/scientists-discover-gene-therapy-provides-neuroprotection-to-prevent-glaucoma-vision-loss/2479407/daily0.7https://beta.crstoday.com/news/holland-foundation-for-sight-restoration-launched-to-provide-life-changing-eye-surgeries/2479402/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-to-present-clinical-data-at-ascrs/2479403/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-introduces-veritas-vision-system-with-features-to-address-key-unmet-needs-in-cataract-surgery/2479401/daily0.7https://beta.crstoday.com/news/sight-sciences-announces-multiple-presentations-at-ascrs/2479400/daily0.7https://beta.crstoday.com/news/glaukos-featured-in-numerous-scientific-abstracts-at-ascrs/2479399/daily0.7https://beta.crstoday.com/news/alcon-reinforces-strength-of-ophthalmology-portfolio-with-surgical-device-scientific-presence-at-ascrs/2479398/daily0.7https://beta.crstoday.com/news/eyemd-emr-healthcare-systems-introduces-edge-computing-at-the-ascrs-annual-meeting/2479397/daily0.7https://beta.crstoday.com/news/arcscan-signs-agreement-for-11-15-million-preferred-series-b-investment-with-shanghai-haohai-biological-technology/2479394/daily0.7https://beta.crstoday.com/news/surface-ophthalmics-announces-25-million-private-round-of-fundraising/2479393/daily0.7https://beta.crstoday.com/news/alcon-to-share-new-data-and-live-booth-presentations-at-ascrs/2479391/daily0.7https://beta.crstoday.com/news/spyglass-pharma-appoints-industry-veteran-patrick-mooney-as-chief-executive-officer/2479389/daily0.7https://beta.crstoday.com/news/refractive-surgery-council-reports-strongest-h1-laser-vision-correction-lvc-procedure-volume-growth-in-nearly-a-decade/2479384/daily0.7https://beta.crstoday.com/news/eyepoint-pharmaceuticals-receives-preliminary-extension-to-pass-through-payment-status-for-dexycu/2479385/daily0.7https://beta.crstoday.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-the-2021-ascrs/2479386/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-to-present-scientific-data-validating-improved-surgical-outcomes-and-legacy-mgd-treatment-at-ascrs/2479387/daily0.7https://beta.crstoday.com/news/bausch-lomb-to-present-14-scientific-posters-featuring-new-analyses-involving-its-surgical-technologies-at-ascrs-2021/2479382/daily0.7https://beta.crstoday.com/news/euclid-systems-appoints-vance-thompson-md-as-chief-medical-officer/2479383/daily0.7https://beta.crstoday.com/news/novabay-pharmaceuticals-partners-with-harrow-healths-imprimisrx-to-promote-prescription-avenova/2479378/daily0.7https://beta.crstoday.com/news/allegro-ophthalmics-to-present-the-results-of-alg-1007-ex-u-s-phase-2-clinical-trial-for-dry-eye-disease-at-ascrs/2479379/daily0.7https://beta.crstoday.com/news/fda-sets-january-deadline-to-decide-on-full-approval-of-pfizer-biontech-vaccine/2479380/daily0.7https://beta.crstoday.com/news/harrow-health-granted-two-patents-for-novel-surgical-dilation-formulation/2479377/daily0.7https://beta.crstoday.com/news/prevent-blindness-holds-10th-annual-focus-on-eye-health-national-summit/2479376/daily0.7https://beta.crstoday.com/news/istar-medical-receives-fda-approval-to-begin-trial-for-miniject-for-patients-with-glaucoma/2479375/daily0.7https://beta.crstoday.com/news/heru-bolsters-executive-team-with-seasoned-industry-veterans/2479373/daily0.7https://beta.crstoday.com/news/hoya-vision-care-and-myopia-profile-training-the-visionaries-of-the-future/2479370/daily0.7https://beta.crstoday.com/news/dopavision-closes-e12-million-series-a-round-to-advance-digital-childhood-myopia-therapeutic-through-clinical-trials/2479372/daily0.7https://beta.crstoday.com/news/aurion-biotech-appoints-professor-shigeru-kinoshita-md-phd-to-its-medical-advisory-board/2479369/daily0.7https://beta.crstoday.com/news/first-eye-care-focused-spac-lifelong-vision-to-host-launch-event/2479368/daily0.7https://beta.crstoday.com/news/zeiss-introduces-fully-integrated-data-driven-medical-ecosystem/2479366/daily0.7https://beta.crstoday.com/news/cats-tonometer-receives-fda-clearance-for-disposable-tonometer-prism/2479364/daily0.7https://beta.crstoday.com/news/nicox-appoints-robert-n-weinreb-md-and-sanjay-g-asrani-md-to-its-glaucoma-clinical-advisory-board/2479362/daily0.7https://beta.crstoday.com/news/ocuphire-to-present-at-multiple-ophthalmic-conferences-in-july/2479363/daily0.7https://beta.crstoday.com/news/ama-assigns-cpt-code-to-software-designed-to-treat-adult-amblyopia-lazy-eye/2479361/daily0.7https://beta.crstoday.com/news/bausch-lomb-launches-biotrue-hydration-boost-lubricant-eye-drops-and-biotrue-micellar-eyelid-cleansing-wipes/2479359/daily0.7https://beta.crstoday.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/daily0.7https://beta.crstoday.com/news/fda-cdc-say-no-need-for-covid-19-booster-vaccines-in-us-at-this-time/2479358/daily0.7https://beta.crstoday.com/news/sight-sciences-pitches-150m-ipo-for-its-glaucoma-dry-eye-devices/2479355/daily0.7https://beta.crstoday.com/news/mikajaki-partners-with-segula-technologies-to-develop-ophthalmic-diagnosis-device/2479353/daily0.7https://beta.crstoday.com/news/pfizer-plans-to-seek-fda-nod-for-covid-19-booster-next-month-as-delta-spreads/2479354/daily0.7https://beta.crstoday.com/news/belkin-laser-announces-corporate-name-change-to-belkin-vision/2479352/daily0.7https://beta.crstoday.com/news/cognivue-initiates-nationwide-clinical-study-to-assess-post-covid-19-syndrome-long-haul-syndrome/2479351/daily0.7https://beta.crstoday.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/daily0.7https://beta.crstoday.com/news/ocugen-climbs-on-phase-3-covid-vaccine-data-hitting-back-at-delta-variant/2479348/daily0.7https://beta.crstoday.com/news/love-your-eyes-theme-of-2021-world-sight-day/2479345/daily0.7https://beta.crstoday.com/news/novasight-announces-establishment-of-three-unique-cpt-codes-for-the-curesight-digital-treatment-for-lazy-eye/2479343/daily0.7https://beta.crstoday.com/news/cvc-capital-partners-viii-to-invest-in-rayner/2479340/daily0.7https://beta.crstoday.com/news/oasis-tears-pf-plus-preservative-free-lubricant-eye-drops-now-delivered-in-a-bottle/2479338/daily0.7https://beta.crstoday.com/news/nicox-to-receive-2-million-from-ocumension-as-milestone-payment-under-zerviate-agreement/2479339/daily0.7https://beta.crstoday.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial-2/2479337/daily0.7https://beta.crstoday.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479335/daily0.7https://beta.crstoday.com/news/gensight-biologics-reports-topline-results-from-reflect-phase-3-trial-confirming-lumevoq-efficacy/2479336/daily0.7https://beta.crstoday.com/news/ascrs-insurance-company-policy-delays-sight-restoring-surgery-puts-patients-in-jeopardy/2479334/daily0.7https://beta.crstoday.com/news/oyster-point-pharma-announces-preclinical-data-highlighting-potent-activity-of-oc-01-varenicline-and-oc-02-simpinicline-against-sars-cov-2-virus-and-variants/2483621/daily0.7https://beta.crstoday.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/daily0.7https://beta.crstoday.com/news/new-aph-partnership-with-humanware-leads-to-creation-of-dynamic-tactile-device/2483620/daily0.7https://beta.crstoday.com/news/ocuphires-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints/2479332/daily0.7https://beta.crstoday.com/news/bausch-lomb-specialty-vision-products-business-expands-access-to-scleralfil-solution-for-patients/2483619/daily0.7https://beta.crstoday.com/news/essilorluxottica-announces-decision-to-close-acquisition-of-grandvision/2483618/daily0.7https://beta.crstoday.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/daily0.7https://beta.crstoday.com/news/roches-actemra-gains-fda-emergency-use-in-hospitalized-covid-19-patients/2479324/daily0.7https://beta.crstoday.com/news/nicoxs-licensee-bausch-lomb-receives-approval-for-vyzulta-in-the-united-arab-emirates/2479326/daily0.7https://beta.crstoday.com/news/study-finds-recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults/2479323/daily0.7https://beta.crstoday.com/news/santen-receives-fda-approval-for-verkazia-for-the-treatment-of-vernal-keratoconjunctivitis/2479321/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-announces-launch-of-tecnis-synergy-and-tecnis-synergy-toric-ii-pc-iols-in-us-and-canada/2479320/daily0.7https://beta.crstoday.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/daily0.7https://beta.crstoday.com/news/sciencebased-health-announces-new-ophthalmology-clinical-advisory-panel/2479314/daily0.7https://beta.crstoday.com/news/coopervision-announces-uniform-markings-across-blanchard-onefit-family-of-scleral-lenses/2479312/daily0.7https://beta.crstoday.com/news/william-j-link-phd-named-chairman-of-allegro-ophthalmics-board-of-directors/2479313/daily0.7https://beta.crstoday.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/daily0.7https://beta.crstoday.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/daily0.7https://beta.crstoday.com/news/tarsus-pharmaceuticals-announces-positive-results-of-saturn-1-trial-evaluating-tp-03-for-the-treatment-of-demodex-blepharitis/2479309/daily0.7https://beta.crstoday.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/daily0.7https://beta.crstoday.com/news/zubisoft-launches-new-iol-treatment-planner/2479307/daily0.7https://beta.crstoday.com/news/us-looks-to-spur-advances-in-covid-19-antivirals-with-3-2-billion-infusion/2479304/daily0.7https://beta.crstoday.com/news/santen-to-host-dry-eye-disease-panel-at-inaugural-european-dry-eye-society-congress-eudec/2479305/daily0.7https://beta.crstoday.com/news/alcons-ora-system-reaches-2-million-cases/2479303/daily0.7https://beta.crstoday.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-first-phase-3-clinical-trial-of-netarsudil-ophthalmic-solution-in-japan/2479300/daily0.7https://beta.crstoday.com/news/lenz-therapeutics-debuts-with-47-million-series-a-financing/2479301/daily0.7https://beta.crstoday.com/news/the-vision-council-releasese280afresults-of-the-2020-internet-influence-report/2479298/daily0.7https://beta.crstoday.com/news/two-shots-of-pfizer-astrazeneca-covid-19-vaccines-effective-against-delta-variant-study/2479295/daily0.7https://beta.crstoday.com/news/market-scope-ophthalmic-laser-market-expected-to-total-376-4-million-in-2021/2479296/daily0.7https://beta.crstoday.com/news/eyenovia-highlights-recent-progress-in-three-phase-3-programs-nda-review-progress-and-licensing-agreements/2479294/daily0.7https://beta.crstoday.com/news/visus-therapeutics-announces-executive-leadership-appointments-in-operations-research-clinical-operations-and-intellectual-property/2479290/daily0.7https://beta.crstoday.com/news/schwind-receives-sme-innovation-award-in-germany/2479288/daily0.7https://beta.crstoday.com/news/eyegate-pharma-announces-first-patient-dosed-for-pp-001-in-a-phase-2-proof-of-concept-ocular-surface-inflammation-study/2479289/daily0.7https://beta.crstoday.com/news/reed-exhibitions-unveils-new-brand-identity/2479287/daily0.7https://beta.crstoday.com/news/randy-jackson-patient-advocates-to-share-stories-of-managing-eye-health-while-thriving-with-diabetes-during-live-virtual-event/2479286/daily0.7https://beta.crstoday.com/news/ocugen-to-no-longer-pursue-eua-for-covid-19-vaccine-candidate-covaxin-will-pursue-full-approval/2479283/daily0.7https://beta.crstoday.com/news/us-to-buy-500-million-doses-of-pfizer-biontech-covid-19-vaccine-for-donation-to-poorest-nations/2479284/daily0.7https://beta.crstoday.com/news/ocuphire-added-to-the-russell-microcap-index/2479285/daily0.7https://beta.crstoday.com/news/glaukos-completes-patient-enrollment-in-us-nda-phase-3-clinical-trials-for-idose-tr/2479280/daily0.7https://beta.crstoday.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/daily0.7https://beta.crstoday.com/news/lighthouse-guild-announces-the-naming-of-the-dorothy-strelsin-behavioral-health-clinic/2479278/daily0.7https://beta.crstoday.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/2479277/daily0.7https://beta.crstoday.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/daily0.7https://beta.crstoday.com/news/glaukos-announces-australias-tga-regulatory-approval-for-preserflo-microshunt/2479276/daily0.7https://beta.crstoday.com/news/jj-vision-announces-launch-of-tecnis-eyhance-toric-ii-iol-with-tecnis-simplicity-delivery-system-in-europe/2479274/daily0.7https://beta.crstoday.com/news/bausch-lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software/2479271/daily0.7https://beta.crstoday.com/news/ocuphire-announces-appointment-of-jay-s-pepose-md-phd-to-its-board-of-directors/2479272/daily0.7https://beta.crstoday.com/news/international-sports-vision-association-and-macuhealth-offer-new-educational-resource-on-sports-nutrition-for-your-eyes/2479270/daily0.7https://beta.crstoday.com/news/high-caffeine-consumption-may-be-associated-with-increased-risk-of-blinding-eye-disease/2479268/daily0.7https://beta.crstoday.com/news/lighthouse-guild-starts-construction-on-new-technology-center/2479265/daily0.7https://beta.crstoday.com/news/scientists-use-video-games-to-shed-light-on-the-link-between-motor-activity-and-vision/2479266/daily0.7https://beta.crstoday.com/news/even-inactive-thyroid-eye-disease-adversely-impacts-patients/2479264/daily0.7https://beta.crstoday.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/daily0.7https://beta.crstoday.com/news/vsy-biotechnology-announces-launch-of-the-enova-c-haptic-model-iol/2479260/daily0.7https://beta.crstoday.com/news/oyster-point-announces-preclinical-study-results-and-pipeline-expansion-with-etf-gene-therapy-for-ocular-surface-diseases/2479258/daily0.7https://beta.crstoday.com/news/coopervision-expands-leadership-team/2479259/daily0.7https://beta.crstoday.com/news/acufocus-appoints-industry-leader-john-garland-as-global-vice-president-of-sales/2479257/daily0.7https://beta.crstoday.com/news/salvat-completes-phase-3-clinical-trials-of-its-new-ophthalmic-corticosteroid-nanoemulsion/2479254/daily0.7https://beta.crstoday.com/news/avellino-launches-avagen-as-first-genetic-test-to-quantify-keratoconus-risk-and-presence-of-corneal-dystrophies/2479255/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-expands-sight-for-kids-program-and-unveils-vision-for-good-community-impact-report/2479256/daily0.7https://beta.crstoday.com/news/bausch-health-and-clearside-biomedical-announce-fda-filing-acceptance-for-xipere/2479252/daily0.7https://beta.crstoday.com/news/who-grants-emergency-listing-to-sinovacs-coronavirus-vaccine/2479253/daily0.7https://beta.crstoday.com/news/myra-vision-closes-17m-in-series-a-financing-to-advance-glaucoma-device/2479247/daily0.7https://beta.crstoday.com/news/neurophth-therapeutics-and-hopstem-biotechnology-partner-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-ocular-diseases/2479248/daily0.7https://beta.crstoday.com/news/gensight-biologics-announces-publication-of-indirect-comparison-showing-treatment-effect-of-lumevoq-versus-natural-history/2479249/daily0.7https://beta.crstoday.com/news/nicoxs-completes-pre-defined-enrollment-of-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479250/daily0.7https://beta.crstoday.com/news/gsk-sanofi-start-phase-3-study-of-covid-19-vaccine-candidate/2479245/daily0.7https://beta.crstoday.com/news/ihealthscreen-announces-ce-mark-for-ipredict-automated-ai-system-for-early-diagnosis-of-dr-amd-and-glaucoma-suspect/2479244/daily0.7https://beta.crstoday.com/news/eyeon-eye-tracking-device-wins-2021-edge-ai-and-vision-product-of-the-year-award/2483617/daily0.7https://beta.crstoday.com/news/burgeoning-sales-of-dilation-drops-to-bolster-ophthalmic-eye-drops-market-growth-future-market-insights-study/2483616/daily0.7https://beta.crstoday.com/news/lighthouse-guild-awards-college-scholarships-to-students-who-are-blind/2483615/daily0.7https://beta.crstoday.com/news/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microline-for-the-treatment-of-presbyopia/2479241/daily0.7https://beta.crstoday.com/news/why-cant-americans-buy-contact-lenses-from-vending-machines/2479238/daily0.7https://beta.crstoday.com/news/study-finds-pfizer-astrazenecas-covid-19-vaccines-highly-effective-against-indian-variant/2479237/daily0.7https://beta.crstoday.com/news/okayama-university-research-high-levels-of-television-exposure-affect-visual-acuity-in-children/2479236/daily0.7https://beta.crstoday.com/news/scientists-new-research-may-revolutionize-cataract-treatment/2479235/daily0.7https://beta.crstoday.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/daily0.7https://beta.crstoday.com/news/eversight-awards-2020-2021-eye-vision-research-grants/2479233/daily0.7https://beta.crstoday.com/news/heru-series-a-funding-accelerates-cloud-and-ai-enabled-wearable-vision-diagnosis-and-therapy/2479231/daily0.7https://beta.crstoday.com/news/alcon-data-highlights-benefits-of-specific-acrysof-models/2479232/daily0.7https://beta.crstoday.com/news/glaukos-expands-its-preserflo-microshunt-relationship-with-santen-via-new-license-agreement/2479228/daily0.7https://beta.crstoday.com/news/oxford-finance-provides-125-million-credit-facility-to-kala-pharmaceuticals/2479229/daily0.7https://beta.crstoday.com/news/the-childrens-eye-foundation-of-aapos-debuts-the-curious-eye-interactive-storybook/2479230/daily0.7https://beta.crstoday.com/news/schwind-atos-receives-winner-award-at-the-german-innovation-awards-2021/2479226/daily0.7https://beta.crstoday.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/daily0.7https://beta.crstoday.com/news/ocuphire-granted-two-new-us-patents-covering-late-stage-drug-candidate-nyxol-including-for-the-treatment-of-presbyopia/2479225/daily0.7https://beta.crstoday.com/news/roche-receives-fda-authorization-for-testing-of-asymptomatic-people-with-the-obas-sars-cov-2-test/2479223/daily0.7https://beta.crstoday.com/news/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-specticle-lens/2479220/daily0.7https://beta.crstoday.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/daily0.7https://beta.crstoday.com/news/three-companies-combine-to-form-corza-medical/2479217/daily0.7https://beta.crstoday.com/news/multicenter-retrospective-study-examines-imprimisrxs-proprietary-klarity-c-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2479218/daily0.7https://beta.crstoday.com/news/sifi-and-bausch-health-russia-announce-strategic-commercial-partnership/2479213/daily0.7https://beta.crstoday.com/news/eyetech-digital-systems-releases-the-eyeon-open-eye-tracking-platform/2479214/daily0.7https://beta.crstoday.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/daily0.7https://beta.crstoday.com/news/arctic-vision-announces-exclusive-licensing-agreement-with-actualeyes/2479210/daily0.7https://beta.crstoday.com/news/regentree-announces-additional-results-from-arise-3-using-rgn-259-for-the-treatment-of-dry-eye/2479211/daily0.7https://beta.crstoday.com/news/new-study-identifies-more-people-with-vision-loss-and-blindness-than-previously-estimated/2479206/daily0.7https://beta.crstoday.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/daily0.7https://beta.crstoday.com/news/cdc-endorses-use-of-pfizer-biontech-covid-19-vaccine-in-teens-as-young-as-12/2479204/daily0.7https://beta.crstoday.com/news/nust-misis-scientists-say-they-developed-a-safe-drug-to-treat-eye-inflammation/2479203/daily0.7https://beta.crstoday.com/news/tilak-healthcare-launches-us-pilot-for-odysight-medical-vision-monitoring-app/2479202/daily0.7https://beta.crstoday.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/daily0.7https://beta.crstoday.com/news/euclid-systems-launches-new-euclid-max-ortho-k-lens/2479200/daily0.7https://beta.crstoday.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-announces-fda-approval-of-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2479199/daily0.7https://beta.crstoday.com/news/ocuphire-completes-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-combination-with-low-dose-pilocarpine-for-treatment-of-presbyopia/2479197/daily0.7https://beta.crstoday.com/news/rvl-pharmaceuticals-upneeq-wins-2021-medtech-breakthrough-award/2479196/daily0.7https://beta.crstoday.com/news/heine-omega-600-indirect-ophthalmoscope-launched-in-the-uk/2479195/daily0.7https://beta.crstoday.com/news/fda-authorizes-pfizer-biontechs-covid-19-vaccine-for-younger-adolescents/2479191/daily0.7https://beta.crstoday.com/news/zeiss-celebrates-175th-anniversary-in-2021/2479194/daily0.7https://beta.crstoday.com/news/innovegas-emacula-system-shows-potential-to-increase-independence-for-visually-impaired/2479190/daily0.7https://beta.crstoday.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/daily0.7https://beta.crstoday.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds-2/2479186/daily0.7